

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7605698

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
EAGLE BIOLOGICS, INC.	11/08/2019
RECEIVING PARTY DATA	
Name:	JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Street Address:	10 SOUTH DEARBORN
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60603
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	15516074
Application Number:	15903635
Application Number:	15903523
Application Number:	15890044
Application Number:	15809602
CORRESPONDENCE DATA	
Fax Number:	(214)981-3400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	214-981-3483
Email:	dclark@sidley.com
Correspondent Name:	DUSAN CLARK, ESQ.
Address Line 1:	SIDLEY AUSTIN LLP
Address Line 2:	2021 MCKINNEY AVE., SUITE 2000
Address Line 4:	DALLAS, TEXAS 75201
ATTORNEY DOCKET NUMBER:	036084-30257
NAME OF SUBMITTER:	DUSAN CLARK
SIGNATURE:	/Dusan Clark/
DATE SIGNED:	10/24/2022
Total Attachments: 4	

source=Eagle Pharma 2019 Confirmatory Grant of SI in Patents (Eagle Biologics, Inc.)#page1.tif
source=Eagle Pharma 2019 Confirmatory Grant of SI in Patents (Eagle Biologics, Inc.)#page2.tif
source=Eagle Pharma 2019 Confirmatory Grant of SI in Patents (Eagle Biologics, Inc.)#page3.tif
source=Eagle Pharma 2019 Confirmatory Grant of SI in Patents (Eagle Biologics, Inc.)#page4.tif

**CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS**

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (the "Confirmatory Grant") is made effective as of November 8, 2019 by and from EAGLE BIOLOGICS, INC., a Delaware corporation (the "Grantor"), to and in favor of JPMORGAN CHASE BANK, N.A., (the "Grantee") for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below).

WHEREAS, Eagle Pharmaceuticals, Inc., a Delaware corporation (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated January 26, 2017, as amended and restated by the Amended and Restated Credit Agreement dated August 8, 2017 and as further amended and restated by the Second Amended and Restated Credit Agreement dated as of the date hereof (and as may be further amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Borrower, the Grantor and the other Loan Parties have entered into a Pledge and Security Agreement dated January 26, 2017, as amended and restated by the Amended and Restated Pledge and Security Agreement dated as of the date hereof (and as may be further amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor owns the patents (the "Patents") listed on Exhibit A attached hereto, which Patents are issued or pending with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been granted in conjunction with the security interest granted to Grantee under the Security Agreement. The rights and remedies of Grantee with respect to the security interest granted herein are without prejudice to and are in addition to those set forth in the Security Agreement and the other Loan Documents, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) Definitions. All capitalized terms not defined herein shall have the respective meanings given to them in the Credit Agreement.

2) The Security Interest.

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of all the Secured Obligations. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations that have not yet arisen), Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to Grantor all reasonably requested instruments in writing or otherwise, releasing the security interest in the Patents acquired under this Confirmatory Grant.

(b) The Grantor hereby grants to Grantee a security interest in (1) all of Grantor's right, title and interest in and to the Patents now owned or from time to time after the date hereof owned or acquired by the Grantor, together with (2) all proceeds and products of the Patents, and (3) all causes of

action arising prior to or after the date hereof for infringement of the Patents or unfair competition regarding the same.

3) Counterparts. This Confirmatory Grant may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

4) Governing Law. This Confirmatory Grant and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant of Security Interest in United States Patents effective as of the date first written above.

EAGLE BIOLOGICS, INC.

By: 
Name: Pete Meyers
Title: Chief Financial Officer

CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS
Exhibit A - SCHEDULE OF PATENTS

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
20180228831 15516074	16-AUG-2018 31-MAR-2017	POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY- LOWERING AGENTS	EAGLE BIOLOGICS, INC.	PUBLISHED
20180177876 15903635	28-JUN-2018 23-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING THIAMINE	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180177875 15903523	28-JUN-2018 23-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING CIMETIDINE	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180153997 15890044	07-JUN-2018 06-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180085463 15809602	29-MAR-2018 10-NOV-2017	LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED